TORONTO, May 14 /CNW/ - Microbix Biosystems Inc. (TSX:MBX) today
announced results for the second quarter ended March 31, 2008, and outlined
steps that have been taken in implementing its strategic business plan.
"We have made significant progress in moving VIRUSMAX(TM) and Urokinase
into the market since the first quarter, and we expect to reach important
milestones with SST(TM)in the coming months. Our base Virology business
continues to support our pipeline development activities with strong cash
flows from this division," said Microbix CEO William J. Gastle.
